← Oncology Approval Tracker

FDA DECISION ·

Scemblix

asciminib · Novartis

Accelerated approvalNew therapyChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Oct 12, 2022

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia after at least two tyrosine kinase inhibitors.

LAMPGEN ANALYSIS

Why it matters

The initial accelerated action added an allosteric BCR::ABL1 inhibitor after two prior TKIs. FDA granted traditional approval on October 12, 2022.

What research teams should watch

Record previous TKIs and why each was discontinued and distinguish the separate T315I indication.

PRIMARY RECORDS

Sources